List of Excipients in Branded Drug PRYIDOSTIGMINE BROMIDE

Generic Drugs Containing PRYIDOSTIGMINE BROMIDE

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	ALCOHOL
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	FD&C BLUE NO. 1
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	FD&C RED NO. 40
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	GLYCERIN
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	LACTIC ACID
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	RASPBERRY

What are the Most Frequently-Used Excipients in PRYIDOSTIGMINE BROMIDE?

# Of NDCs	Excipient
3	ALCOHOL
3	FD&C BLUE NO. 1
3	FD&C RED NO. 40
3	GLYCERIN
3	LACTIC ACID
3	RASPBERRY

Pyridostigmine Bromide Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Pyridostigmine bromide is an established acetylcholinesterase inhibitor with low active-ingredient cost, extensive generic competition, and limited compound-patent protection. Commercial opportunity is concentrated in differentiated delivery systems, excipient-enabled tolerability, preservative-free liquid products, modified-release formulations, pediatric and geriatric presentations, military stockpile supply, and combination packaging rather than in a new chemical entity.

The strongest development strategy is a low-risk oral solid dosage form using a robust immediate-release platform, followed by an extended-release or liquid product if clinical and regulatory economics support the investment. Excipient selection should address dose uniformity, moisture sensitivity, gastrointestinal tolerability, tablet swallowability, stability, and patient adherence.

What is pyridostigmine bromide used for?

Pyridostigmine bromide is the bromide salt of pyridostigmine, a reversible acetylcholinesterase inhibitor. It increases acetylcholine concentrations at neuromuscular junctions and is primarily used for symptomatic treatment of myasthenia gravis.

The product is marketed in several oral dosage forms:

Dosage form	Representative strength	Commercial use
Immediate-release tablet	60 mg	Standard maintenance therapy
Lower-strength tablet	30 mg	Dose titration and sensitive patients
Extended-release tablet	180 mg	Reduced dosing frequency
Oral solution or suspension	Product-dependent	Pediatric, geriatric, dysphagia, and institutional use
Injectable pyridostigmine products	Jurisdiction-dependent	Specialized hospital or military applications

Mestinon is the reference brand most associated with pyridostigmine bromide in the United States. Generic pyridostigmine bromide tablets are also marketed. FDA-approved labeling identifies myasthenia gravis as the principal approved indication for oral products.[1,2]

Pyridostigmine bromide has also been used by the U.S. military as a pretreatment against soman nerve-agent exposure. That use is separate from the standard chronic treatment market and has different procurement, stability, packaging, and stockpile requirements.[3]

What excipients are used in pyridostigmine bromide tablets?

Pyridostigmine bromide tablets generally use conventional pharmaceutical excipients because the active ingredient is potent at a relatively low dose and does not require an advanced delivery technology for immediate release.

Common excipient classes include:

Excipient class	Typical examples	Primary function
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Tablet mass and dose uniformity
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Corn starch, crospovidone, sodium starch glycolate	Tablet breakup
Lubricant	Magnesium stearate, stearic acid	Ejection and manufacturing efficiency
Glidant	Colloidal silicon dioxide	Powder flow
Antiadherent	Talc	Manufacturing process control
Film former	Hypromellose	Appearance, protection, swallowing
Plasticizer	Polyethylene glycol	Film flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, approved dyes	Identification and product appearance

Product-specific inactive ingredients differ by manufacturer, strength, and dosage form. FDA labeling for branded and generic products should control any formulation comparison because two products with the same active ingredient can use materially different diluents, coatings, lubricants, and disintegrants.[1,2] FDA’s Inactive Ingredient Database is the primary public reference for previously approved excipient levels and routes of administration.[4]

What excipient issues are most important for pyridostigmine bromide?

The main formulation issues are dose uniformity, tablet robustness, dissolution, taste, gastrointestinal tolerability, and excipient sensitivity.

Pyridostigmine treatment often involves repeated daily dosing. A formulation that reduces nausea, abdominal cramping, diarrhea, or swallowing difficulty may have commercial value even when the active ingredient is identical to generic tablets. The product should not delay release unless the clinical objective is a true extended-release profile.

Lactose is widely used in oral solid formulations, but lactose-free development may have value for patients with intolerance or for institutions seeking simplified excipient declarations. Magnesium stearate is a standard lubricant but can affect tablet wetting and dissolution when overused. High lubricant levels should be evaluated during scale-up.

For a low-dose 30 mg tablet, content uniformity and segregation control are more important than they are for a high-load formulation. Direct compression may be feasible if powder flow and blend uniformity are adequate. Wet granulation can improve uniformity and tablet strength but adds water exposure and process complexity.

What is the best immediate-release excipient strategy?

A practical immediate-release platform would use a conventional direct-compression or dry-granulation process with:

• Microcrystalline cellulose or lactose as the principal diluent
• Crospovidone or sodium starch glycolate as the disintegrant
• Povidone or pregelatinized starch if additional binding is needed
• Colloidal silicon dioxide for flow
• Magnesium stearate at a controlled concentration
• A film coat based on hypromellose for identification and swallowability

The excipient system should be selected through comparative dissolution, blend-uniformity, friability, hardness, moisture uptake, and accelerated-stability testing. The target is rapid, consistent release across physiologically relevant pH conditions.

A low-cost generic strategy should avoid unnecessary excipients, complex coating systems, and novel manufacturing steps. A differentiated strategy can justify a more expensive platform if it supports a claim or measurable patient benefit, such as:

• Smaller tablet size
• Easier swallowing
• Reduced tablet burden
• Improved stability in hot and humid climates
• Absence of lactose, gluten-derived ingredients, or selected dyes
• Better dose flexibility through scored tablets
• Taste masking for liquid products

What formulations are protected or commercially differentiated?

The original pyridostigmine compound and the traditional immediate-release tablet technology are mature. Commercial differentiation is more likely to come from formulation, dosage form, manufacturing process, or device-related intellectual property than from basic composition-of-matter rights.

Opportunity	Potential differentiation	Patent strength
Immediate-release tablet	Excipients, tablet geometry, scoring, coating, process controls	Low to moderate
Extended-release tablet	Matrix or multiparticulate release system	Moderate if clinically differentiated
Oral solution	Preservative system, taste masking, pH control, stability	Moderate
Ready-to-use suspension	Physical stability and dosing device	Moderate
Orally disintegrating tablet	Superdisintegrant and taste-masking technology	Moderate
Sprinkle formulation	Multiparticulates for dysphagia patients	Moderate
Transdermal or depot delivery	Alternative route and sustained exposure	High technical risk
Combination product	Co-packaged or fixed-dose therapy	Moderate to high, depending on claim scope

The 180 mg extended-release product is commercially important because it reduces dosing frequency. A new formulation would need to demonstrate a clinically meaningful release profile and support appropriate bioequivalence or clinical bridging. FDA’s modified-release guidance places emphasis on in vitro dissolution, food effects, dose dumping, alcohol interaction, and pharmacokinetic comparability.[5]

When does pyridostigmine bromide lose exclusivity?

Pyridostigmine bromide has been marketed for decades, and the core active-ingredient exclusivity has expired. The United States market is therefore primarily a generic market, subject to any surviving product-specific patents, regulatory exclusivities, or approved labeling restrictions.

The relevant exclusivity categories are:

Exclusivity type	Pyridostigmine bromide position
New chemical entity exclusivity	Expired
Original compound patent	Expired
Traditional immediate-release product protection	Generally expired or commercially weak
Extended-release formulation protection	Must be assessed by product and jurisdiction
Method-of-use patents	Potentially relevant only for narrowly claimed new uses
Orphan exclusivity	No broad, current orphan barrier is generally associated with standard myasthenia gravis treatment
Pediatric exclusivity	Product-specific and historical, if granted
Regulatory exclusivity for generic entry	Generally not a major barrier for established products

A Paragraph IV challenge would have the greatest commercial value against a still-protected extended-release, liquid, or other differentiated product. An ANDA applicant could challenge listed patents by alleging invalidity, unenforceability, or non-infringement under the Hatch-Waxman framework.[6]

What is the Orange Book status of pyridostigmine bromide?

The Orange Book identifies FDA-approved drug products, reference-listed drugs, therapeutic equivalence ratings, and certain patent and exclusivity information. Pyridostigmine bromide products may be listed under specific manufacturer, dosage form, strength, and application entries rather than under a single consolidated product record.

For commercial diligence, the relevant checks are:

1. The reference-listed drug for each strength and dosage form.
2. Therapeutic-equivalence ratings for generic tablets.
3. Any listed patents for extended-release products.
4. Any labeling differences affecting substitution.
5. Whether a proposed product is an ANDA, 505(b)(2), or NDA candidate.
6. Whether the proposed formulation falls within the same dosage-form category as the reference product.

Immediate-release generic tablets generally face lower regulatory risk than an extended-release product or novel liquid because the development path is more established. A 505(b)(2) pathway may be relevant for a new dosage form, alternative route, or modified formulation that relies partly on existing pyridostigmine data but is not suitable for a conventional ANDA.[7]

How strong is the patent estate for pyridostigmine bromide?

The core patent estate is weak from a new-product perspective because the compound and basic oral dosage form are old. The remaining opportunity is a secondary patent estate built around:

• Controlled-release matrices
• Multiparticulate systems
• Taste-masked liquid formulations
• Preservative-free packaging
• Stabilized aqueous formulations
• Device-assisted dosing
• Specific excipient ratios
• Manufacturing processes
• Narrow method-of-use claims

Secondary patents must provide more than routine optimization. A patent claiming a conventional tablet with standard excipients may face obviousness and lack-of-inventive-step challenges. Stronger claims would link the formulation to a measurable technical effect, such as improved stability, lower impurity formation, reduced dosing variability, or a defined pharmacokinetic profile.

Patent term should be assessed by family, jurisdiction, terminal disclaimers, patent-term adjustment, patent-term extension, continuations, and prosecution history. Patent rights in the United States, European Union, Japan, and emerging markets will not necessarily expire on the same date.

What commercial opportunities exist for pyridostigmine bromide?

1. Patient-friendly immediate-release tablets

A small, scored, film-coated tablet can target patients who need frequent dose adjustment. Commercial value may come from ease of swallowing and reliable tablet splitting rather than from a new pharmacological effect.

2. Extended-release products

Extended-release pyridostigmine can reduce dosing frequency and nighttime treatment burden. The principal risks are variable gastrointestinal transit, food effects, dose dumping, and difficulty demonstrating meaningful clinical benefit over low-cost immediate-release generics.

3. Preservative-free oral liquid

A preservative-free solution or unit-dose suspension could address pediatric, geriatric, enteral-feeding, and dysphagia markets. Packaging is central to the strategy. Unit-dose cups, oral syringes, and tamper-evident containers can improve dosing accuracy and reduce contamination risk.

4. Taste-masked pediatric formulation

Pyridostigmine’s bitterness can limit adherence in liquid products. Ion pairing, flavor systems, polymeric taste-masking, and coated multiparticulates are possible approaches. The formulation must maintain dose uniformity and avoid delayed or incomplete release.

5. Military and stockpile supply

The military market values long-term stability, rapid deployment, high-temperature performance, packaging durability, and supply assurance. A product with a validated extended shelf life and unit-dose packaging may have greater procurement value than a conventional commercial bottle.

6. International market expansion

Pyridostigmine remains relevant in markets where myasthenia gravis treatment access is uneven. Opportunities may exist in low-cost tablets, hospital supply, and regional manufacturing. Regulatory filings must account for local reference products, pharmacopeial standards, language requirements, and climatic stability zones.

Which manufacturers and competitors affect the market?

The competitive set includes the branded Mestinon franchise, generic pyridostigmine bromide tablet suppliers, regional manufacturers, hospital suppliers, and companies developing alternative cholinesterase-inhibitor products.

Competition is based on:

• Unit price
• Supply reliability
• Tablet strengths
• Availability of 180 mg extended-release tablets
• Liquid or dysphagia-friendly dosage forms
• Contract manufacturing capacity
• Regulatory approvals in target countries
• Wholesaler and hospital formulary access

The main commercial threat is substitution by low-priced immediate-release generics. A new entrant should therefore avoid competing solely on active-ingredient price unless it has a manufacturing-cost advantage or a reliable institutional supply contract.

What generic entry risks exist?

Generic entry risk is high for conventional immediate-release tablets. A generic applicant can typically rely on established pharmacology, mature analytical methods, and known excipient classes. Price erosion is likely where multiple suppliers have therapeutic-equivalence ratings and unrestricted substitution.

Risk is lower, but development cost is higher, for:

• Extended-release tablets
• Oral liquids with robust stability
• Preservative-free products
• Pediatric formulations
• Sprinkle or multiparticulate products
• Military-specific packaging and shelf-life configurations

A differentiated product must establish a defensible regulatory position and protect the formulation with claims tied to technical performance. A simple “new excipient combination” is unlikely to sustain premium pricing without a clear patient or manufacturing benefit.

How does pyridostigmine bromide compare with competing therapies?

Therapy	Main role	Commercial implication
Pyridostigmine bromide	Symptomatic cholinesterase inhibition	Low-cost, established first-line support
Prednisone and corticosteroids	Immunosuppression	Competes for disease-control treatment, not direct symptomatic substitution
Azathioprine, mycophenolate, tacrolimus	Steroid-sparing immunosuppression	Long-term disease management
Eculizumab and ravulizumab	Targeted biologic therapy for selected patients	High-cost, specialist-managed treatment
Efgartigimod and related agents	Advanced immune-directed therapy	Premium segment with different treatment objectives
Amifampridine	Different neuromuscular indication	Limited direct substitution

Pyridostigmine remains commercially relevant because it is oral, familiar, comparatively inexpensive, and used across disease-severity categories. Biologics do not eliminate the need for symptomatic therapy in all patients.

What is the revenue exposure for a new pyridostigmine product?

Public revenue data for individual generic pyridostigmine products are often unavailable because sales are reported within broader company portfolios. The addressable market is commercially modest relative to major chronic medicines but can support niche profitability when manufacturing, regulatory, and distribution costs are controlled.

Revenue potential is strongest where a product captures one of four premiums:

1. Lower total treatment burden through extended release.
2. Better administration for dysphagia or enteral feeding.
3. Institutional or military procurement.
4. Reliable supply in markets with limited generic availability.

A conventional tablet without a cost, supply, or usability advantage is unlikely to generate significant premium revenue.

Key Takeaways

• Pyridostigmine bromide is a mature, genericized active ingredient with expired core exclusivity.
• Excipients should prioritize dose uniformity, rapid disintegration, stability, and gastrointestinal tolerability.
• The most credible immediate-release platform uses conventional diluents, disintegrants, glidants, lubricants, and an optional film coat.
• Extended-release, liquid, pediatric, preservative-free, and military-stockpile products offer the clearest commercial differentiation.
• Generic entry risk is high for standard tablets and lower for technically differentiated dosage forms.
• Secondary patent protection must rely on demonstrable formulation or manufacturing advantages.
• The strongest business cases combine regulatory simplicity with a clear adherence, supply, or administration benefit.

FAQs About Pyridostigmine Bromide Formulation and Commercial Strategy

Can lactose-free pyridostigmine bromide tablets be commercially differentiated?

Yes. A lactose-free tablet can target patients with excipient intolerance and institutions seeking simplified ingredient profiles. The differentiation is commercial rather than pharmacological and must be supported by reliable tablet performance and an adequate distribution strategy.

Is an oral solution more attractive than an extended-release tablet?

The answer depends on the target market. An oral solution has stronger value for dysphagia, pediatric, geriatric, and enteral-feeding patients. An extended-release tablet has broader adult-market potential but faces greater pharmacokinetic and bioequivalence risk.

Can an excipient combination alone support a pyridostigmine patent?

It can, but routine substitution of common excipients is vulnerable to obviousness challenges. Stronger patent positions require defined composition ranges linked to unexpected stability, dissolution, bioavailability, or manufacturing results.

Does pyridostigmine bromide require a biosimilar strategy?

No. Pyridostigmine bromide is a small-molecule drug, not a biologic. The relevant pathways are generally an ANDA, NDA, or 505(b)(2) application rather than a biosimilar application.

What is the highest-value manufacturing barrier for pyridostigmine bromide?

For standard tablets, manufacturing is relatively accessible. The strongest barriers are validated long-term stability, controlled-release performance, preservative-free liquid stability, specialized packaging, and reliable supply at institutional or military scale.

References

1. U.S. Food and Drug Administration. (2023). Mestinon pyridostigmine bromide prescribing information.
2. DailyMed. (2024). Pyridostigmine bromide tablet and extended-release tablet labeling. National Library of Medicine.
3. U.S. Food and Drug Administration. (2002). Pyridostigmine bromide use for military pretreatment against soman nerve agent exposure.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
5. U.S. Food and Drug Administration. (2003). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
7. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).